Introduction
Individuals exposed to high doses of acute total or partial body irradiation face life-threatening injury to their haematopoietic and gastrointestinal tissue systems (Dorr and Meineke, 2011) . With excellent supportive care, individuals may partially recover from the haematopoietic acute radiation syndrome (H-ARS) and gastrointestinal ARS but later succumb to the delayed effects of acute radiation exposure (DEARE), specifically radiation pneumonitis/fibrosis (Baranov et al., 1994; Hirama et al., 2003; Uozaki et al., 2005) . DEARE of the lung is characterized by an acute inflammatory reaction (pneumonitis) 2-6 months post-exposure which can cause severe debilitating or life-threatening respiratory complications or chronic fibrosis that may develop months to years later and result in diminished quality of life (Gross, 1977; Van Dyk et al., 1981; Williams et al., 2012) .
BIO 300 (Humanetics Corporation), a patent-protected nanosuspension formulation that contains synthetic genistein nanoparticles, is being developed to mitigate and/or treat DEARE in the lung (radiation pneumonitis/pulmonary fibrosis). Genistein, the active ingredient in BIO 300, has been shown to reduce collagen deposition and protect against biomarkers of delayed lung sequelae following total body or organ-specific irradiation in rodents Calveley et al., 2010) . When administered 24 h prior to total body irradiation in C57BL/6J mice, genistein (200 mg·kg À1 ; s.c.) has been shown to reduce micronuclei formation in primary fibroblasts and lessen the formation of collagen-rich lesions in the irradiated lungs of animals surviving the H-ARS . However, the efficacy of genistein when administered post-radiation has been limited, in part, due to its limited dissolution in water (Yang et al., 2012) . To improve its solubility and thus plasma/tissue pharmacokinetics, the genistein in BIO 300 has been wet-milled to an average particle size of 0.2 μm. The studies were designed to determine whether nanoparticle genistein (BIO 300) is efficacious when administered after radiation exposure. In support of this, when administered prophylactically, BIO 300 has been shown to dramatically increase bone marrow cellularity and accelerate recovery of the haematopoeitic stem and progenitory cell clonogenicity and improve survival from the H-ARS (25% vehicle-treated vs. 95% BIO 300-treated) when administered 24 h prior to total body irradiation (Ha et al., 2013) .
In the current study, BIO 300 was delivered at a dose of 200 or 400 mg·kg À1 starting 24 h post-whole thorax lung irradiation (WTLI) for a duration of 2, 4, 6, or in some cases 10, weeks to determine the best dose and treatment duration to maximally improve survival in age-and sex-matched pneumonitis-and fibrosis-prone C57L/J mice. The C57L/J mouse strain was chosen based on extensive model development that has shown this strain reacts over a time period and dose range that covers the responses seen in non-human primates (Garofalo et al., 2014) and humans (Fryer et al., 1978; Van Dyk et al., 1981) , with the pneumonitis reaction progressing to a pathology of fibrosis (Jackson et al., 2010; . Determination of therapeutic efficacy took into account changes in respiratory physiology, gross morphology and histological evaluation of lung damage and overall survival following radiation exposure. Results indicated that BIO 300 at a dose of 400 mg·kg À1 for a duration of 4-6 weeks was the best treatment schedule to reduce morbidity and improve survival following exposure to lethal doses of thoracic irradiation.
Methods

Animals
Age-and sex-matched C57L/J mice (Jackson Labs, Bar Harbour, ME, USA) at approximately 10-14 weeks of age on the day of irradiation were used in this study. C57L/J mice were chosen based on previous studies demonstrating that lung damage in this strain replicates the radiation dose-response, temporal progression and pathogenesis of radiation pneumonitis and fibrosis in human lung following similar doses of thoracic irradiation (Jackson et al., 2010; . All experiments were conducted in compliance with the Animal Use Protocol approved by the Institutional Animal Care and Use Committee. Also, animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Animals were identified by unique numbers found on individual ear tags and by cage card. Mice were housed five per cage in microisolator cages containing certified direct-contact bedding (Harlan Teklad soft cob bedding, ¼ 00 corn cob with enrichment). Animals were provided hyperchlorinated water (10 ppm) and fed certified commercial laboratory animal phyto-free chow ad libitum throughout the study (Harlan Teklad 2914). Animal holding rooms were maintained at 21 ± 3°C with 30-70% relative humidity. A 12 h light/dark cycle was maintained with lights being turned on at approximately 0700 h and off at approximately 1900 h.
Sample size considerations, randomization and blinding
A schematic diagram of the study design is presented in Figure 1 . Sample size considerations were determined based on a Mantel-Haenszel test. Using 30 mice (15 male and 15 female) per WTLI group, there was 90% power to detect an odds ratio of 3.3 and a Bonferroni adjustment (i.e. nominal α = 0.025) for the comparison of each treatment group to the control. An odds ratio of 0.33 is equivalent to a decrease in mortality for the treated mice of approximately 27% compared to the control mice. In this study, 510 age-and sexmatched mice were allocated to one of two irradiation groups: 11 and 12.5 Gy whole thorax lung irradiation. A total of 130 female and 40 male mice were allocated to the shamirradiated group (age-and sex-matched controls). Females were further randomized to one of three major groups to receive (1) vehicle only (BIO 300 without the active ingredient, nanomilled genistein); (2) BIO 300, 200 mg·kg À1 ; or (3) BIO 300, 400 mg·kg À1 starting 24 h post-sham or WTLI. Animals in the BIO 300 treatment groups were further randomized to one of four different daily treatment duration groups (2, 4, 6 or 10 weeks). Male mice were randomized into only a single BIO 300 daily treatment group (400 mg·kg À1 ) and further randomized to receive drug treatment for 2, 4, 6 or 10 weeks. Mice were allocated so that no more than two mice per group were randomized into each cage.
Radiation delivery and quality control
Mice weighing ≥20 g were anaesthetized by i.p. injection of 80-100 mg·kg À1 ketamine and 10-15 mg·kg À1 xylazine 15 min prior to radiation exposure to prevent them moving out of the field. C57L/J mice were exposed to 11.0 or 12.5 Gy of 320 kVp X-rays to the whole thorax (1.25 Gy·min À1 , HVL = 1 mm Cu, Pantak 320 X-ray Irradiator, Precision X-ray). Following WTLI, animals were randomized to treatment groups (n = 28-31 per group). A calibration quality check was performed each morning and again in between each radiation run. Port films (Gafchromic EBT2 dosimetry film) were acquired during each radiation run to verify that the lungs of each mouse were properly positioned within the radiation field.
Test and control article treatment
BIO 300 was administered daily (7 days·week À1 ; weekends and holidays included) by oral gavage at a dose of 200 or 400 mg·kg À1 starting 24 h after radiation exposure for a duration of 2, 4, 6 or, in some cases, 10 weeks. BIO 300 was provided by Humanetics Corporation at a concentration of 325 mg·mL À1 and was diluted on site with BIO 300 vehicle to the required concentration depending on the dose. This diluted suspension was mixed by vortexing (Analog Vortex, VWR) for 2 min before being administered at 0.02 mL·g
À1
body weight. The average biweekly body weight for each of the study groups was used to determine the volume to be administered. The volume administered was calculated based on the concentration of the diluted suspension and did not exceed the total volume of 0.5 mL per animal. Retention samples (n = 6) of the diluted suspension were shipped to Pace Analytical Life Sciences (Oakdale, MN, USA) for analysis of genistein and related substances. All samples met analysis specification. The diluted suspension, stable for 5 days at 4°C, was prepared every fifth day. Humanetics Corporation provided the vehicle control article ready to be used. Each animal received a vehicle dose calculated based on the average biweekly body weight for that group and did not exceed a total volume of 0.5 mL total per gavage. The vehicle was administered in the same manner as the test article.
Animal observation and euthanasia criteria
Animal health was monitored and recorded daily, 7 days per week. Body weight was acquired every 2 weeks. All animals were monitored daily during the in-life phase by personnel experienced in recognizing signs of morbidity (appearance and behavioural criteria). The decision to kill was made using the following criteria: body weight loss >20% (single criteria) or a combination of (1) body weight loss with no recovery within 2 days; (2) inactivity over 2 days; (3) lack of grooming that worsens over 24 h; (4) enhanced pause (Penh) >2.5 × baseline; or (5) persistent hunched posture. Standard methods were used to kill the animals (>100 mg·kg
À1
sodium pentobarbital administered i.p. followed by thoracotomy after cessation of respiration for >1 min) and were applied to moribund animals. These methods are consistent with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association (1986). All female C57L/J mice were killed between day 180 and 182 post-irradiation. Male C57L/J mice were followed for up to 220 days post-exposure, because of the potential for a longer latency period in male versus female mice based on prior studies, after which all surviving animals were killed.
Respiratory function
Respiratory function was assessed every 2 weeks during the course of the in-life phase using an unrestrained, noninvasive whole body plethysmograph (WBP; Buxco Research System, Wilmington, NC, USA). Two pre-irradiation measurements were recorded to determine baseline respiratory function across all animals. For WBP, mice were allowed to acclimatize in a barometric chamber for 5 min, and the recording of the breathing pattern was performed for 10 min.
Gross morphology and histopathology
At the time of death, a bilateral thoracotomy was performed on each animal. Gross morphology of the heart and lungs was assessed and documented. Pleural effusions were measured after which the lungs and heart were removed. Lungs Figure 1 Schematic diagram of the experimental design. The objective of this study was to determine the best dose and duration of BIO 300 treatment to reduce major morbidity and improve the likelihood of survival following exposure to lethal doses of WTLI in a C57L/J mouse model. For this study, 510 animals were distributed among two irradiation groups (11.0 and 12.5 Gy) and one sham-irradiation group (0 Gy). Following sham -or WTLI, animals were distributed to the following treatment groups: (1) Control (no vehicle or BIO 300); (2) Vehicle (females only); (3) BIO 300 (200 mg·kg À1 ); and (4) BIO 300 (400 mg·kg À1 ). Animals distributed to the BIO 300 groups were further allocated to four treatment duration groups for continuation of daily treatment for 2, 4, 6 or 10 weeks (w). Due to the complexity of the study, experiments were staggered. In male mice, the 200 mg·kg À1 and 10 w treatment duration groups were terminated prematurely as 400 mg·kg À1 for 4+ weeks administration was superior to 200 mg·kg À1 for 4+ weeks in female mice. Furthermore, no statistically significant difference was observed between the 6 and 10 week treatment groups. Females were followed for up to 180 days and male mice for up to 220 days. At the time of scheduled or unscheduled death, lung tissue was harvested, weighed and processed for microscopic examination.
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were separated into left and right lobes and individually weighed. Heart weights were documented. The left lung was rinsed in PBS, inflated with 10% neutral buffered formalin and placed in 10% formalin for fixation. The right lung was snap frozen in liquid nitrogen and stored at -80°C for future analysis. The heart was fixed in 10% neutral buffered formalin and paraffin embedded for histopathology at a later time. 
Endpoints
The primary endpoint for the study was a significant improvement in survival in the BIO 300 treatment group compared to its control. The secondary endpoint was a reduction in major morbidity, including differences in latency, incidence, severity and duration of radiation-induced lung injury following WTLI exposure.
Statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . The proportion of sex-matched mice that survived for 180 days was computed for each radiation dose and treatment group. The mean and median survival times are presented by radiation dose and treatment group. Kaplan-Meier survival curves are used to present survival data by treatment group. Survival analysis was performed using Cox proportional hazards regression modelling. Survival was measured as time from radiation to death, with survival time censored at a maximum of 180 days (scheduled death at end of observation period of 180-220 days). Predictor variables of survival included animal gender and treatment group [indicator/dummy variable coding of the group variable (control, 2 week duration, 4 week duration and 6 week duration), with the control group serving as the reference group for each comparison]. To assess the model assumption of proportional hazards, Schoenfeld residual plots were examined, and the correlation between the scaled Schoenfeld partial residuals for each covariate and log failure times was tested for statistical significance. The assumption of proportional hazards was upheld for all the Cox regression models reported here. Secondary breathing parameters were examined using descriptive statistics (mean, SD, median, maximum and minimum) at each time point. Groups were compared using one-way ANOVA followed by Tukey-Kramer tests for pairwise multiple comparisons between different groups. A two-tailed independent groups t-test was used to compare mean lung weight between survivors (killed at pre-determined study endpoint of 26 weeks) and decedents (killed because of major morbidity) in each group. Additional analysis for differences between dose-level cohorts and differences between survivors versus decedents within each dose-level cohort was performed. P < 0.05 was set as the level of statistical significance for all tests.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 .
Results
BIO 300 at a dose of 400 mg·kg À1 was superior to 200 mg·kg À1 for improving the likelihood of survival after WTLI exposure The 400 mg·kg À1 dose level, 11 Gy radiation level. Survival for all animals was calculated based on 180 days. For animals exposed to 11.0 Gy WTLI and treated with 400 mg·kg À1 BIO 300 daily, the Cox regression model revealed that each of the three treatment duration groups significantly increased survival versus the control group. Hazard ratios (HR) for all three comparisons showed a >50% reduction in the risk of mortality in treated animals versus controls (2 week duration vs. controls: HR = 0.43, 95% CI 0.19-0.97, P = 0.042; 4 week duration vs. controls: HR = 0.38, 95% CI 0.16-0.92, P = 0.031; 6 week duration vs. controls: HR = 0.39, 95% CI 0.17-0.89, P = 0.026). The greatest improvement in survival relative to controls at the 180 days post-WTLI study endpoint was observed in the 4 weeks duration group (26.6% difference in survival vs. controls), followed by the 6 weeks duration treatment group (14.5% improvement in survival) ( Figure 2A ). The 20% improvement in male survival when BIO 300 was given for 4 weeks was not statistically significant (HR vs. controls = 0.38, 95% CI 0.09-1.51, P = 0.17) ( Figure 2B ). In female mice, there was a statistically significant improvement in survival when BIO 300 was given for 6 weeks (HR vs. controls = 0.34, 95% CI 0.19-0.99, P = 0.048) ( Figure 2C ). No statistically significant treatment by sex interaction effects were identified.
The 400 mg·kg À1 dose level, 12.5 Gy radiation level. At the higher radiation dose of 12.5 Gy (~LD90/180), BIO 300 given daily for a total of 4 or 6 weeks improved survival by 18 and 26% respectively, relative to survival in controls at 180 day study endpoint (Figure 2A ). In both male and female C57L/J mice, pneumonitis appeared to resolve by 180 days post-WTLI at the radiation doses used in this study ( Figure 2B, C) . Between 180 and 220 days, only three male mice in total succumbed to pneumonitis/fibrosis in all the radiation (11.0 and 12.5 Gy) groups combined (data not shown). The loss of animals did not significantly impact data interpretation of the results. Results from the Cox regression model indicated a significant reduction in the risk of mortality for 4 week treatment duration (vs. controls) Figure 2 (A) Kaplan-Meier curves for 180 day survival for age-and sex-matched C57L/J mice exposed to WTLI. Following 11 Gy WTLI, animals that were treated with BIO 300 (400 mg·kg À1 ) for a duration of 4 weeks (w) showed improvement in survival by 26.6% compared with untreated controls. A similar improvement was observed in animals treated for 6 weeks post-radiation. The in-life period for male mice was extended to 220 days. During the 40 day extended follow-up, only one mouse succumbed to pneumonitis. Similarly, following 12.5 Gy WTLI, animals that were treated with BIO 300 (400 mg·kg À1 ) for a duration of 6 weeks showed improvement in survival by 26.0% compared with untreated controls; (B) 180 day survival of male C57L/J mice post-WTLI. Following 11.0 Gy WTLI, no statistical significant improvement in survival was observed following any length of BIO 300 treatment in male mice. BIO 300 treatment for 4-6 weeks post-12.5 Gy WTLI improved survival in male mice; (C) 180 day survival of female C57L/J mice post-WTLI. BIO 300 treatment for 6 weeks post-11 Gy WTLI improved survival in female mice. Following 12.5 Gy WTLI, no statistically significant improvement in survival was observed following any length of BIO 300 treatment in female mice. *P < 0.05.
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(HR = 0.40, 95% CI 0.18-0.91, P = 0.030) and for 6 week treatment duration (vs. controls) (HR = 0.41, 95% CI 0.18-0.92, P = 0.032) but not for the 2 week treatment duration (vs. controls) (HR = 0.53, 95% CI 0.24-1.18, P = 0.119). The 13.7% improvement in female survival when BIO 300 was given for 4 weeks was not statistically significant (HR vs. controls = 0.44, 95% CI 0.19-1.01, P = 0.053) ( Figure 2C ). In male mice, there was a statistically significant improvement in survival when BIO 300 was given for 4 weeks (HR vs. controls = 0.42, 95% CI 0.18-0.99, P = 0.047) and for 6 weeks (HR vs. controls = 0.21, 95% CI 0.08-0.54, P = 0.001) ( Figure 2B ). There were no statistically significant treatment by sex interaction effects. Pulmonary oedema and congestion, signs of acute pneumonitis, was lowered with 4-6 weeks of BIO 300 (400 mg·kg À1 ) treatment
At the time of scheduled or unscheduled euthanasia, lung weights were recorded as a marker of oedema and congestion. The mean lung weight among sham-irradiated control mice was 179.4 ± 6.6 mg. Untreated animals displayed a significant increase in lung weight following exposure to 11.0 or 12.5 Gy WTLI. No significant differences were observed among BIO 300 treated versus untreated groups exposed to 11.0 Gy WTLI. However, 6 weeks oral administration of BIO 300 starting 24 h post-exposure to 12.5 Gy significantly (P < 0.05, one-way ANOVA with Tukey-Kramer multiple comparisons tests) reduced pulmonary oedema and congestion in sex-matched animals ( Figure 3A ). Likewise in male C57L/J mice exposed to 12.5 Gy, 6 weeks of BIO 300 (400 mg·kg À1 ) treatment significantly decreased lung weight (P < 0.05, one-way ANOVA with Tukey-Kramer multiple comparisons tests, Figure 3B ). The lung weight of irradiated, untreated female C57L/J mice were~2.5-fold greater than those of shamirradiated controls of the same age, irrespective of WTLI dose ( Figure 3C ). There was a trend towards a decrease in lung weight in female C57L/J mice exposed to 12.5 Gy WTLI and treated with 200 mg·kg À1 BIO 300 starting 24 h post-exposure for a duration of 4 weeks (P = 0.08, Tukey-Kramer; data not shown).
Temporal analysis of respiratory rate and Penh demonstrates that BIO 300 preserves lung function following thoracic irradiation
Unrestrained animals were acclimatized to the plethysmography chamber, and baseline measurements were recorded during a 2 week period prior to the day of irradiation. Respiratory function was assessed biweekly starting 2 week post-exposure for the duration of the follow-up period post-exposure. A clear increase in Penh, a unitless measurement of lung function, was observed between weeks 18 and 25 postexposure to 11 Gy WTLI ( Figure 4A , B) and weeks 14 and 24 post-exposure to 12.5 Gy WTLI ( Figure 4C , D) in both males and females. This increase in Penh coincides with the onset of the acute pneumonitis phase, which results in organ failure and ultimately death or, with therapeutic intervention, can resolve and lead to recovery from WTLI. Respiratory distress observed in animals between 14 to 25 weeks postexposure is consistent with the onset of acute pneumonitis and major morbidity. Analysis of the change in breathing frequency between the pre-irradiation baseline respiratory rate and week 16 demonstrates a dose-dependent increase in the slope over time from 0.10 among sham-irradiated controls to 0.42 and 0.58 for 11.0 and 12.5 Gy WTLI respectively ( Figure 4E ). In male mice exposed to 11.0 and 12.5 Gy WTLI, 6 weeks of BIO 300 treatment significantly mitigated respiratory distress ( Figure 4F ). A reduction in the slope of the change from the baseline frequency line indicates improved respiratory function and less respiratory distress. In female C57L/J mice exposed to 12.5 Gy WTLI, BIO 300 administered for 6 or 10 weeks post-exposure significantly reduced respiratory distress compared to BJP I L Jackson et al.
untreated animals. However, 10 weeks of treatment was not significantly better than 6 weeks. No significant BIO 300-mediated improvements in respiratory distress were observed in females exposed to 11 Gy WTLI. The slopes of the change in respiratory frequency for each study cohort are listed in Figure 4F .
Figure 3
Pulmonary oedema and congestion, indicated by wet lung weights at the time of scheduled or unscheduled death, across radiation and BIO 300 treatment groups. (A) In sex-matched animals exposed to 12.5 Gy, there was a significant reduction in pulmonary oedema/congestion when BIO 300 was administered for a total of 6 weeks starting 24 h post-exposure. (B) The reduction was primarily driven by the ameliorating effect of BIO 300 in the lungs of male C57L/J mice. (C) There was no significant difference in lung weight between test-article versus control-article treated groups in female mice. Error bars represent ± SEM.
Figure 4
Longitudinal changes in respiratory function following 11Gy or 12.5 Gy WTLI. (A) Respiratory rate (breaths per minute, bpm) was elevated in all animals between weeks 18 and 26 regardless of BIO 300 treatment following exposure to 11.0 Gy WTLI. (B) Administration of BIO 300 at a daily dose of 400 mg·kg À1 starting 24 h post-exposure reduced Penh, a measurement of respiratory distress, compared to 11.0 Gy WTLI alone in ageand sex-matched C57L/J mice. (C) Respiratory frequency in age-and sex-matched C57L/J mice administered BIO 300 at a dose of 400 mg·kg
À1
starting 24 h post-exposure to 12.5 Gy WTLI for a duration of 6 weeks (w) was lower compared to animals not receiving treatment intervention. (D) Penh was most effected by BIO 300 (400 mg·kg À1 ) when administered for 6 weeks duration following high dose radiation exposure to the whole thorax. (E) Representative images show the % change in respiratory frequency compared to the baseline at each time point post-WTLI. A radiation dose-dependent increase in the % change from baseline (CFB) was observed. (F) Table describing the median % change in baseline ± SEM broken down by radiation dose, treatment group and animal sex. Six weeks duration of BIO 300 was the most effective regime for reducing radiation-related increase in respiratory rate in both females and males following 12.5 Gy WTLI and in males following a dose of 11.0 Gy WTLI (P < 0.05).
Microscopic examination of tissue demonstrated reduced alveolitis in BIO 300-treated animals compared to the non-treated controls
Normal alveolar structure with clear airways was observed in sham-irradiated mice. Microscopic exam of lung tissue from non-treated WTLI animals displayed damage consistent with acute pneumonitis including mononuclear cell inflammation, interstitial oedema and congestion and fibrosis ( Figure 5) . A modest reduction in the level of inflammation and airway fibrosis was observed in the irradiated lungs of mice treated with BIO 300 for 2 weeks, whereas the lungs of animals administered BIO 300 treatment for 4 to 6 weeks post-WTLI showed a greater reduction in the extent of lung damage. The residual remaining damage was localized to focal areas within the tissue compared to the severe, diffuse inflammation observed in non-treated irradiated controls. The lungs of animals treated with BIO 300 (400 mg·kg À1 ) for 4 weeks displayed the greatest reduction in damage with clearly evident areas of normal, well-aerated lung.
Discussion
The development of medical countermeasures to save lives in the aftermath of a nuclear and/or radiological accident or attack is an urgent, unmet need. Here, we report on the results of a dose-finding and treatment-optimization study with BIO 300 nanosuspension (active pharmaceutical ingredient -genistein) to reduce major morbidity/mortality from lethal radiation pneumonitis/fibrosis in a well-established murine model (Jackson et al., 2010; (Figure 1 ). The rationale for using BIO 300 to ameliorate radiationinduced lung injury stems from more than a decade of work demonstrating the efficacy of genistein to mitigate radiation toxicity in rodent models of total body and partial body exposures (Davis et al., 2007 Calveley et al., 2010; Mahmood et al., 2011 Mahmood et al., , 2013 . In rodent models of WTLI, genistein has been shown to reduce micronuclei formation and decrease levels of oxidative stress, reduce proinflammatory and pro-fibrotic cytokine expression (e.g. TNF-α, IL-1β and TGF-β) and lower collagen content (Para et al., 2009; Calveley et al., 2010) . Para et al. found that genistein administered in the diet reduced micronuclei formation, macrophage accumulation and collagen deposition in the lungs of mice following fractionated irradiation. However, although genistein partially reduced the extent of fibrosis, it had minimal effect on pneumonitis (Para et al., 2009 ). This is not necessary unexpected as numerous studies have shown dissociation of pulmonary fibrosis from lethality in mice after WTLI (Dabjan et al., 2016) . These data suggest radiation pneumonitis and fibrosis are not inextricably linked, with the primary cause of lethality in preclinical rodent models, as in humans, being acute pneumonitis. In this study, we utilized a murine model of WTLI that progresses through a phase of acute, potentially lethal, pneumonitis (primary endpoint) followed by late fibrosis (secondary endpoint). The effect of BIO 300 on each pathology is reported.
One of the primary challenges in developing genistein as a therapeutic is its insolubility in water, thereby reducing the bioavailability of genistein and thus its efficacy. BIO 300 is manufactured using a patent-protected nanomilling process, reducing the active ingredient, genistein, to an average particle size of <0.2 μm. A series of pharmacokinetic experiments in mice and canines has shown that BIO 300 nanosuspension is dramatically more orally bioavailable than non-nano genistein formulations. In mice, a twofold improvement in drug exposure (AUC) for total genistein was observed following a single dose of BIO 300 nanosuspension compared to non-nanomilled genistein. Data in the current study demonstrate a positive trend in morbidity/mortality outcomes among animals treated with an oral dose of 400 mg·kg À1 BIO 300, daily, for a duration of 4 to 6 weeks starting 24 h post-exposure. The timing of drug initiation is consistent with the current U.S. Concept of Operations for a mass casualty event in which forward deployment of medical countermeasures is likely to be delayed.
Survival was calculated based on a 180 day post-exposure follow-up. Cox-regression analysis showed a significant improvement in 180 day survival following WTLI in age-and sex-matched C57L/J mice with BIO 300 400 mg·kg À1 for 4 weeks following 11.0 Gy WTLI. Among the 4 week treatment cohort, 180 day survival was approximately 62% (18/29) compared to 36% survival in the non-treated control group (11/31) ( Figure 2A) . A similar improvement was observed at the higher dose of 12.5 Gy WTLI where survival was 29-37% in the 4-6 week BIO 300 treatment cohorts (8/28 and 11/30) versus only 11% in the control group (3/28) ( Figure 2A ). The observed improvement in survival was supported by a significant reduction in respiratory dysfunction during the period of acute pneumonitis when BIO 300 was given at a dose of 400 mg·kg À1 for 6 weeks starting 24 h post-exposure ( Figure 4F ).
In male mice, the follow-up period was extended to 220 days because of a predicted longer latency period prior to the manifest illness stage in male mice compared to female mice, which is routinely observed in the C57BL/6J strain (Dabjan et al., 2016) . However, no differences in the latency period between sexes were observed in this study consistent with earlier reports using the C57L/J strain (Jackson et al., 2014) . Therefore, all data were analysed using the 180 day cut-off.
At the lower BIO 300 dose of 200 mg·kg À1 , the likelihood of survival was increased by 14% in female mice exposed to 11.0 Gy WTLI, but only when the treatment duration was extended to 10 weeks post-exposure (Table 1) . At 12.5 Gy WTLI, 1 out of 13 female mice (8%) survived to 180 days without treatment intervention compared with only 2-3 out of 15 mice (13-20%) among those receiving 4, 6 or 10 weeks duration of BIO 300 treatment. Taken together, 200 mg·kg À1 demonstrated a less robust improvement in survival in female mice when compared to treatment with 400 mg·kg À1 BIO 300 for 4 weeks duration (Table 3) . Further, the survival results were compared to data collected on respiratory function measured every 2 weeks during the course of the study using non-invasive unrestrained whole body plethysmography. BIO 300 at a dose of 200 mg·kg À1 had a significant effect on improving respiratory rate during the first several weeks following exposure while animals were still undergoing BIO 300 treatment (data not shown). However, the observed effects of BIO 300 on respiratory function were notably absent 2-4 weeks following treatment completion suggesting 200 mg·kg À1 of BIO 300 modified the early onset of clinical manifestations but did not change the disease trajectory. In male mice, the 200 mg·kg À1 BIO 300 and the 10 week treatment duration cohorts were terminated prematurely based on the aforementioned data in female mice and the limited improvement in survival observed with 400 mg·kg À1 treatment lasting longer than 6 weeks in female mice (lethality: 87.5% WTLI-11 Gy vs. 71.4% WTLI + BIO 300 for 10 weeks, Table 1 and 92.3% WTLI + 12.5 Gy vs. 92.3% WTLI + 10 week BIO 300, Table 1 ). The lack of efficacy, particularly improvement in survival, observed with continuation of treatment past 6 weeks may begin to define the therapeutic treatment window for BIO 300. This suggests that the pathological effects of delayed lung injury are optimally mitigated by BIO 300 within the first 6 weeks following radiation exposure. Future studies will be aimed at better understanding the pharmacodynamic properties of BIO 300-mediated mitigation of delayed lung injury within this treatment window. At the higher dose of 12.5 Gy WTLI, no improvement in survival was observed in BIO 300 (400 mg·kg À1 ) treatment groups in female mice regardless of duration when compared to vehicle-treated controls (Table 4) . However, at a dose of 11.0 Gy, BIO 300 given for 4 or 6 weeks showed a greater survival advantage than vehicle alone. Interpretation of these results suggests that although survival is not significantly different in non-treated female mice between 11.0 and 12.5 Gy, the higher radiation dose causes more extensive tissue damage. The increase in severity of tissue damage between 11.0 and 12.5 Gy is supported by a much greater reduction in air flow as measured by Penh in the 12.5 Gy WTLI cohort compared to the 11.0 Gy cohort in male and female mice and shorter latency periods between the time of irradiation and temporal onset of symptomatic damage at the higher radiation dose (Figure 4 ). Masson's trichrome staining of lung tissue showed evidence of pneumonitis with varying percentage of normal tissue architecture among treatment groups. Pneumonitis was characterized by mononuclear inflammatory cell infiltration, an abundance of foamy, lipid-laden macrophages, oedema/congestion and organized exudation of parenchymal tissue leading to complete occlusion of the vessels and small airways. Histological evaluation suggests that the lungs of BIO 300-treated (400 mg·kg À1 ; 4 weeks duration) animals had less overall tissue damage and a higher percentage of normal lung tissue ( Figure 5 ).
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Importantly, in a more recent canine pharmacokinetic study, the AUC for total genistein following a single 30 mg·kg À1 dose of BIO 300 nanosuspension was approximately five times higher than obtained with non-nanomilled genistein (13 447 vs. 2660 ng-h·mL À1 ) (data not shown). In this canine study, a near-linear dose response was observed over a range of BIO 300 nanosuspension doses (30-500 mg·kg À1 ). In a study conducted by Calveley et al., partial mitigation of the effects of lung irradiation by non-nano genistein did not include improved long-term survival (Calveley et al., 2010) . Compared to the expected serum levels in this study, a comparable dose of BIO 300 would yield a serum concentration~5× higher than that obtained with non-nano genistein. Thus, the improved long-term survival in our BIO 300 studies, correlated with increased oral bioavailability with improved therapeutic outcome. Based on the short serum half-life of BIO 300 in mice (~4 h) and in canines (~7 h), twice-daily dosing would be expected to maintain therapeutic drug levels for a longer duration and thus may further improve drug efficacy. In summary, the results of this study demonstrate that BIO 300 given to C57L/J mice at a daily oral dose of 400 mg·kg À1 , for 4 to 6 weeks, starting 24 h post-11-12.5 Gy whole thorax lung irradiation can significantly improve survival and reduce morbidity associated with radiation pneumonitis/fibrosis. Therefore, future studies will be designed to determine whether an escalation of the BIO 300 dose (>400 mg·kg À1 ) or twice-daily dosing to maintain higher systemic drug levels for a longer period of time could further improve survival from radiation pneumonitis/fibrosis.
